Shanghai Shen Lian Biomedical Corporation Class A
SSSE:6880987.42
CNY
-0.30
(-3.89%)
ISIN
CNE100003P17
Return %
Stock
S&P 500
1Y
-32.11
14.20
3Y
5.70
81.12
5Y
-32.11
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Xu Gao
- Full Time Employees
- 375
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- No. 48 Jiangchuan East Road Shanghai SH China 200241
- IPO Date
- Oct 28, 2019
- Website
- slbio.com.cn
- Similar Companies
- Business
- Shanghai Shen Lian Biomedical Corporation engages in the research, development, production, and sales of veterinary biological products primarily focused on prevention, treatment, and diagnostics for economic animals, pets, and aquatic species. Its core products include vaccines for swine foot-and-mouth disease (Type O and A synthetic peptide vaccines), porcine circovirus type 2 subunit vaccines, swine fever genetically engineered subunit vaccines (CHO-133D), and bovine nodular skin disease inactivated vaccines. The company also produces veterinary diagnostic detection kits for diseases such as foot-and-mouth disease and African swine fever, along with vaccines for lumpy skin disease and other veterinary preventive biological products. It operates two GMP-certified production facilities located in Shanghai and Lanzhou and is designated by the Chinese Ministry of Agriculture and Rural Affairs as an enterprise for foot-and-mouth disease vaccine production. Recent major developments include successful completion of a veterinary drug GMP audit at its Lanzhou branch, acquisition of production approval for a bivalent inactivated vaccine targeting swine streptococcosis and infectious pleuropneumonia, and the launch of Phase II clinical trials for innovative human drug candidates expanding the company's presence in the human biologics sector through strategic collaboration with Shanghai Ben Tiancheng Biopharmaceutical Co. The company also conducted a share repurchase program aimed at employee incentives and long-term development and has strengthened strategic partnerships in China-Africa livestock industry engagement. Furthermore, it received approval for production of a novel swine vaccine against pleuropneumonia and Streptococcus suis, reinforcing its leadership in veterinary vaccine innovation. Founded in 2001 and headquartered in Shanghai, China, Shanghai Shen Lian Biomedical Corporation is a national high-tech enterprise operating mainly within the Chinese market, targeting producers of swine, cattle, sheep, pets, poultry, fish, and shrimp. It is recognized as a top-tier player in veterinary biologics with significant R&D investments and market presence in China, having been the first domestic animal health company listed on the STAR Market. Its ongoing business expansion includes increasing involvement in human biological drug development and contract manufacturing related to synthetic peptides and monoclonal antibodies. The company maintains extensive industry-university-research collaborations to advance technology platforms in veterinary and human biologics. The company’s financial strength is supported by considerable sales revenue and R&D investment fueling innovation and market growth in veterinary health products and diagnostic solutions.